Current Edition

news

PhRMA criticizes ICER in latest skirmish over valuing drugs

Industry lobbying group PhRMA on Thursday warned the use of cost-effectiveness estimates like those developed by the Institute for Clinical and Economic Review could force …

Continue Reading →